Transplantation combined with novel agents optimal treatment for multiple myeloma

Monoclonal antibodies and multiple myeloma

New definition for multiple myeloma improves patient outcomes

Factors influencing response to blinatumomab in relapsed/refractory ALL

Evidence for kinase inhibitor activity in acute myeloid leukaemia

Targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia

First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia

Does the patient with myelofibrosis feel better through pacritinib?

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression

Treatment and survival of patients with chronic myeloid leukaemia in Europe